Lung Cancer Trial, Recruiting (NCT06418412)

Lung Cancer Trial, Recruiting NCT06418412 Sponsor: National Cancer Centre, Singapore Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06418412 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with advanced non-small cell lung cancer (NSCLC), confirmed by a laboratory test on a tissue sample.
You have tested positive for a specific genetic change called an "EGFR exon 20 insertion mutation," detected by any locally approved test.
Your diagnosis was made between 1 January 2013 and 31 December 2024, so that at least 12 months of medical and treatment records are available.
You are an adult male or female, meeting the age requirements set by your local regulations (confirm with trial site).

Who may not be able to join:

You do not have the specific genetic change known as an "EGFR exon 20 insertion mutation."

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aaron C. Tan, MBBS, PhD, National Cancer Centre, Singapore

Phone: +65 6306 1748

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06418412

Sponsor: National Cancer Centre, Singapore

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +65 6306 1748

More information: https://clinicaltrials.gov/study/NCT06418412

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with advanced non-small cell lung cancer (NSCLC), confirmed by a laboratory test on a tissue sample.
You have tested positive for a specific genetic change called an "EGFR exon 20 insertion mutation," detected by any locally approved test.
Your diagnosis was made between 1 January 2013 and 31 December 2024, so that at least 12 months of medical and treatment records are available.
You are an adult male or female, meeting the age requirements set by your local regulations (confirm with trial site).

Who may not be able to join:

You do not have the specific genetic change known as an "EGFR exon 20 insertion mutation."

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Cancer Centre, Singapore

Registry

ClinicalTrials.gov

Start date

15 March 2024

Est. completion

31 December 2026

Where this trial is recruiting

🇸🇬 Singapore 🇰🇷 South Korea 🇹🇼 Taiwan

Primary endpoints

Overall survival (OS); Duration of therapy (DOT); Real-world progression-free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov